Sumitomo Pharma America (SMPA) is focused on delivering therapeutic and scientific breakthroughs in the areas of critical patient need spanning psychiatry & neurology, oncology, urology, women’s health, rare disease, and cell & gene therapies. The company’s diverse portfolio includes several marketed products and a robust pipeline of early- to late-stage assets. Building on Sumitomo Pharma’s 125-year legacy of innovation, SMPA leverages proprietary in-house technology platforms and advanced analytics capabilities to accelerate discovery, development, and help bring novel therapies to patients sooner. SMPA is a Sumitomo Pharma company. For more information, visit http://www.us.sumitomo-pharma.com or visit us on LinkedIn or Twitter.
Sumitomo Pharma America (SMPA) is focused on delivering therapeutic and scientific breakthroughs in the areas of critical patient needs spanning psychiatry & neurology, oncology, urology, women’s health, rare disease, and cell & gene therapies. The company’s diverse portfolio includes several marketed products and a robust pipeline of early-to late-stage assets.